Feeds › 8-K events
8-K events
Major news companies must report to the SEC: results, deals, leadership changes.
About this data
- What it is
- A Form 8-K is how a public company announces major news between its quarterly reports: earnings, an acquisition, a new CEO, a cybersecurity incident. Each filing lists the numbered items it covers.
- Who files it
- The company, usually within four business days of the event.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Many 8-Ks are routine, so the item description is the place to start. Item 9.01, which only lists attached documents, is hidden unless you ask for it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
8-K items filed per day, last 30 days
All items Earnings results (2.02)
One filing can report several items. Item 9.01, which only lists attached documents, is not counted.
Latest 8-K filings
Showing: ticker CXAI
| Filed | Company | Item | Form | Filing |
|---|---|---|---|---|
| Oct 22, 2026 | CXAI CXApp Inc. | 8.01 Other Events | 8-K | 8-K ↗ |
| Oct 22, 2026 | CXAI CXApp Inc. | 3.02 Unregistered Sales of Equity Securities | 8-K | 8-K ↗ |
| Oct 22, 2026 | CXAI CXApp Inc. | 1.01 Entry into a Material Definitive Agreement | 8-K | 8-K ↗ |
| Sep 3, 2026 | CXAI CXApp Inc. | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Sep 3, 2026 | CXAI CXApp Inc. | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule | 8-K | 8-K ↗ |
| Aug 19, 2026 | CXAI CXApp Inc. | 2.01 Completion of Acquisition or Disposition of Assets | 8-K/A | 8-K ↗ |
| Aug 14, 2026 | CXAI CXApp Inc. | 8.01 Other Events | 8-K | 8-K ↗ |
| Aug 14, 2026 | CXAI CXApp Inc. | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 8-K | 8-K ↗ |
| Aug 14, 2026 | CXAI CXApp Inc. | 3.03 Material Modification to Rights of Security Holders | 8-K | 8-K ↗ |
| Jul 6, 2026 | CXAI CXApp Inc. | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K | 8-K ↗ |
| Jul 6, 2026 | CXAI CXApp Inc. | 4.01 Changes in Registrant's Certifying Accountant | 8-K | 8-K ↗ |
| Jun 23, 2026 | CXAI CXApp Inc. | 5.07 Submission of Matters to a Vote of Security Holders | 8-K | 8-K ↗ |
| Jun 3, 2026 | CXAI CXApp Inc. | 3.02 Unregistered Sales of Equity Securities | 8-K | 8-K ↗ |
| Jun 3, 2026 | CXAI CXApp Inc. | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Jun 3, 2026 | CXAI CXApp Inc. | 2.01 Completion of Acquisition or Disposition of Assets | 8-K | 8-K ↗ |
| Jun 3, 2026 | CXAI CXApp Inc. | 1.01 Entry into a Material Definitive Agreement | 8-K | 8-K ↗ |
| May 28, 2026 | CXAI CXApp Inc. | 3.02 Unregistered Sales of Equity Securities | 8-K | 8-K ↗ |
| May 13, 2026 | CXAI CXApp Inc. | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| May 13, 2026 | CXAI CXApp Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Apr 17, 2026 | CXAI CXApp Inc. | 3.02 Unregistered Sales of Equity Securities | 8-K | 8-K ↗ |
| Apr 10, 2026 | CXAI CXApp Inc. | 3.02 Unregistered Sales of Equity Securities | 8-K | 8-K ↗ |
| Mar 26, 2026 | CXAI CXApp Inc. | 3.02 Unregistered Sales of Equity Securities | 8-K | 8-K ↗ |
| Mar 12, 2026 | CXAI CXApp Inc. | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule | 8-K | 8-K ↗ |
| Jan 30, 2026 | CXAI CXApp Inc. | 3.02 Unregistered Sales of Equity Securities | 8-K | 8-K ↗ |
| Dec 12, 2025 | CXAI CXApp Inc. | 3.02 Unregistered Sales of Equity Securities | 8-K | 8-K ↗ |
| Oct 23, 2025 | CXAI CXApp Inc. | 3.02 Unregistered Sales of Equity Securities | 8-K | 8-K ↗ |
| Oct 23, 2025 | CXAI CXApp Inc. | 2.03 Creation of a Direct Financial Obligation | 8-K | 8-K ↗ |
| Oct 23, 2025 | CXAI CXApp Inc. | 1.01 Entry into a Material Definitive Agreement | 8-K | 8-K ↗ |
| Sep 12, 2025 | CXAI CXApp Inc. | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule | 8-K | 8-K ↗ |
| Aug 11, 2025 | CXAI CXApp Inc. | 8.01 Other Events | 8-K | 8-K ↗ |
| Aug 11, 2025 | CXAI CXApp Inc. | 1.01 Entry into a Material Definitive Agreement | 8-K | 8-K ↗ |
| Aug 4, 2025 | CXAI CXApp Inc. | 8.01 Other Events | 8-K | 8-K ↗ |
| Aug 4, 2025 | CXAI CXApp Inc. | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 8-K | 8-K ↗ |
| May 20, 2025 | CXAI CXApp Inc. | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| May 20, 2025 | CXAI CXApp Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| May 20, 2025 | CXAI CXApp Inc. | 5.07 Submission of Matters to a Vote of Security Holders | 8-K | 8-K ↗ |
| Apr 7, 2025 | CXAI CXApp Inc. | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Apr 7, 2025 | CXAI CXApp Inc. | 4.02 Non-Reliance on Previously Issued Financial Statements | 8-K | 8-K ↗ |
| Apr 7, 2025 | CXAI CXApp Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Apr 1, 2025 | CXAI CXApp Inc. | 1.01 Entry into a Material Definitive Agreement | 8-K | 8-K ↗ |
| Mar 31, 2025 | CXAI CXApp Inc. | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Mar 31, 2025 | CXAI CXApp Inc. | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K | 8-K ↗ |
| Jan 2, 2025 | CXAI CXApp Inc. | 3.02 Unregistered Sales of Equity Securities | 8-K | 8-K ↗ |
43 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 4:43 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances